Trial Profile
Multicenter double-blind randomized clinical trial assessing efficacy and safety of exenatide in the treatment of hypothalamic obesity after craniopharyngioma therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Hypothalamic disorders; Obesity
- Focus Therapeutic Use
- Acronyms CRANIOEXE
- 27 Jan 2019 Status changed from recruiting to completed.
- 03 May 2016 New trial record